Germany's Alzchem nine-month sales rise 4% on ingredients demand

Overview

• Germany specialty chemicals firm's nine-month sales rose 4% yr/yr

• Nine-month EBITDA increased 8% yr/yr

• Company confirmed full-year 2026 guidance

Outlook

• Alzchem confirms 2026 sales forecast of about EUR 600 mln

• Company expects 2026 EBITDA of around EUR 126 mln

• Alzchem continues to target 2026 EBITDA margin of about 21.0%

Result Drivers

• HIGH-QUALITY INGREDIENTS DEMAND - Co said sustained demand for high-quality ingredients, especially in nutrition and defense, drove sales growth

• DEFENSE AND NUTRITION SEGMENTS - Co cited strong sales in defense (nitroguanidine) and human nutrition (creatine brands) as main growth contributors

• PRODUCT MIX - Co attributed higher EBITDA margin in specialty chemicals segment to improved product mix

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the specialty chemicals peer group is "buy"

• Wall Street's median 12-month price target for Alzchem Group AG is €201.00, about 23.3% above its October 28 closing price of €163.00

• The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 23 three months ago

Reuters Recommended Reads

• Oct 28 - Germany's Symrise Q3 organic sales rise 5.3% on higher volumes

• Oct 28 - Symrise heads for worst day in eight years on growth, margin woes

• Oct 28 - Norway's Borregaard Q3 EBITDA hits record, beats analyst estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)